Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Bankrupt Orchid Pharma...

    Bankrupt Orchid Pharma Rejects Only Bid for being too low

    Written by Ruby Khatun Khatun Published On 2018-04-24T17:21:38+05:30  |  Updated On 24 April 2018 5:21 PM IST
    Bankrupt Orchid Pharma Rejects Only Bid for being too low

    New Delhi: Orchid pharma has invited a fresh bidding after the company has found the only eligible bid for takeover of the company to be low.


    The development was taken after a meeting was held on April 20, 2018, by the committee of creditors of Orchid Pharma.


    The company has informed BSE that three bids were received by resolution professional on 10th April 2018. Out of these, two bids were found to be non- compliant under Section 29A of The Insolvency and Bankruptcy Code (Amendment) Act, 2017 by resolution professional and thereby stand rejected.


    While in the case of the third bid, which is only the eligible bid, the consideration was found to be low and hence, the committee of creditors rejected the bid.


    The committee of creditors of Orchid Pharma has authorized resolution professional to initiate a fresh round of bidding and with a deadline for submission of resolution plans on or before 5 PM on 25th April ants (Wednesday).


    The company has also said that the resolution applicants who participated in the earlier rounds of bidding are also eligible to participate in this round of bidding.


    ET has reported that the three bids were received from Ingen Capital, Fidelity Trading Corporation which was ineligible and Union Quimico Farmacéutica, the only eligible bid. Union Quimico is a subsidiary of Hyderabad-based Vivimed Labs.


    An official told ET, “Although the bid of Union Quimico Farmacéutica was eligible, lenders were not interested since it offered just about Rs 600 crore payable over 3-6 years.”

    Last year, Orchid Pharma was referred to the bankruptcy court by Lakshmi Vilas Bank in financial claims of Rs 3,500 crore. The company exports active pharmaceutical ingredients (APIs) of antibiotics and has two US Food and Drug Administration-approved manufacturing plants.


    Below is the attachment for the same
    active pharmaceutical ingredientsantibioticsbankruptcycommittee of creditorsFidelity Trading Corporationfresh biddingIngen CapitalLakshmi Vilas BankOrchid PharmarejectUnion Quimico FarmacéuticaVivimed Labs
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok